News articles about Digirad (NASDAQ:DRAD) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Digirad earned a news impact score of 0.04 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 45.9648282737153 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Digirad (NASDAQ:DRAD) remained flat at $$2.30 during trading hours on Tuesday. The stock had a trading volume of 41,100 shares, compared to its average volume of 85,526. Digirad has a 52-week low of $1.90 and a 52-week high of $5.68. The stock has a market capitalization of $46.25, a PE ratio of -3.90 and a beta of 1.87. The company has a quick ratio of 1.07, a current ratio of 1.44 and a debt-to-equity ratio of 0.36.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 28th. Stockholders of record on Thursday, February 15th will be paid a $0.055 dividend. This represents a $0.22 annualized dividend and a dividend yield of 9.57%. The ex-dividend date is Wednesday, February 14th. Digirad’s payout ratio is -37.29%.

DRAD has been the subject of several research analyst reports. ValuEngine cut Digirad from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. TheStreet cut Digirad from a “c” rating to a “d+” rating in a research note on Friday, November 3rd.

In other news, major shareholder Cannell Capital Llc acquired 65,508 shares of Digirad stock in a transaction dated Tuesday, January 23rd. The stock was purchased at an average cost of $2.65 per share, for a total transaction of $173,596.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Digirad (DRAD) Share Price” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2018/02/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-digirad-drad-share-price.html.

Digirad Company Profile

Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center.

Insider Buying and Selling by Quarter for Digirad (NASDAQ:DRAD)

Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.